The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| GLSI | -31.59% | +118.36% | +16.9% | +83% |
| S&P | +15.06% | +95.03% | +14.29% | +104% |
Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.
The top-performing IPO of 2020 is a high-risk, high-reward opportunity, with one drug in its pipeline and one disease in its sights. Is it worth investing in now?
The drop came despite the clinical-stage biotech announcing good news over the weekend.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.00M | 3.0% |
| Market Cap | $121.25M | -45.5% |
| Market Cap / Employee | $15.16M | 0.0% |
| Employees | 8 | 14.3% |
| Net Income | -$4.03M | -54.4% |
| EBITDA | -$4.05M | -52.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $3.13M | -56.7% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00M | 0.0% |
| Short Term Debt | $0.00M | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -347.56% | -235.1% |
| Return On Invested Capital | -167.75% | -175.3% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$2.23M | -113.1% |
| Operating Free Cash Flow | -$2.23M | -113.1% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 31.96 | 29.63 | 25.17 | 91.18 | 110.12% |
| Price to Tangible Book Value | 31.98 | 29.64 | 25.18 | 91.24 | 110.07% |
| Enterprise Value to EBITDA | -67.09 | -17.77 | -37.46 | -29.21 | -63.95% |
| Return on Equity | -151.7% | -342.0% | -515.3% | -491.9% | 297.79% |
| Total Debt | $0.00M | $0.00M | $0.00M | $0.00M | - |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
